Study Summary
The study will evaluate safety and efficacy of the CD22-targeted chimeric antigen receptor modified-T cell(CAR-T) cells in the treatment of B-cell Malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD22-CAR-transduced T cellsBIOLOGICAL
a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Fengtai District | Beijing | Beijing Municipality | China |